tag drug-shortages 
STAT News
OCTOBER 27, 2022
Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, one manufacturer has returned to the market — but is selling its medicine for 10 to 20 times the prices offered by the only other companies with available supplies.
XTalks
NOVEMBER 3, 2022
Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). In the third quarter of 2022, Mounjaro scored $187.3
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JUNE 7, 2023
The drugs were administered open label and all patients were given a low dose of aspirin. The study drug was mailed directly to participants, and at the end of the trial participants were instructed to destroy the drug. The trial took place at 64 sites, and randomized 863 patients. We never had an amendment to the protocol.
pharmaphorum
NOVEMBER 27, 2022
Incidents such as the hormone replacement therapy drug shortage in early 2022 have shown the damaging impact supply chain issues can have on people who depend on these drugs. Mix ups in hand-offs are another large disruptor, especially when drugs have specific shipping requirements. Automation can be such a solution.
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. The drug was approved to treat type 2 diabetes mellitus in May. million in Q3.
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. The drug was approved to treat type 2 diabetes mellitus in May. million in Q3.
The Pharma Data
MAY 4, 2021
Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Lorbrena, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Lorbrena (lorlatinib) — In March 2021, Pfizer announced that the U.S.
Expert insights. Personalized for you.
111 
Let's personalize your content